Zevra Therapeutics Inc (NASDAQ:ZVRA)’s traded shares stood at 0.42 million during the last session, with the company’s beta value hitting 1.93. At the close of trading, the stock’s price was $7.18, to imply a decrease of -1.10% or -$0.08 in intraday trading. The ZVRA share’s 52-week high remains $8.44, putting it -17.55% down since that peak but still an impressive 45.82% since price per share fell to its 52-week low of $3.89. The company has a valuation of $377.81M, with an average of 1.07 million shares in intraday trading volume over the past 10 days and average of 725.23K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Zevra Therapeutics Inc (ZVRA), translating to a mean rating of 1.00. Of 7 analyst(s) looking at the stock, 0 analyst(s) give ZVRA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.42.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Zevra Therapeutics Inc (NASDAQ:ZVRA) trade information
After registering a -1.10% downside in the last session, Zevra Therapeutics Inc (ZVRA) has traded red over the past five days. The 5-day price performance for the stock is -2.58%, and 15.06% over 30 days. With these gigs, the year-to-date price performance is 9.62%. Short interest in Zevra Therapeutics Inc (NASDAQ:ZVRA) saw shorts transact 4.4 million shares and set a 6.24 days time to cover.
Zevra Therapeutics Inc (ZVRA) estimates and forecasts
Looking at statistics comparing Zevra Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Zevra Therapeutics Inc (ZVRA) shares are 5.59% up over the last 6 months, with its year-to-date growth rate lower than industry average at -21.54% against 19.70%. Revenue is forecast to shrink -5.00% this quarter before jumping 20.00% for the next one. The rating firms project that company’s revenue will shrink -2.30% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is 5.35M. Meanwhile, for the current quarter, a total of 5 analyst(s) estimate revenue growth to 13.65M.Earnings reports from the last fiscal year show that sales brought in 2.9M and 13.22M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 84.80% before jumping 3.30% in the following quarter.
ZVRA Dividends
Zevra Therapeutics Inc has its next earnings report out on 2024-Nov-05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
We also have iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Zevra Therapeutics Inc (ZVRA) shares. Going by data provided on Jun 30, 2024 , iShares Russell 2000 ETF holds roughly 1.0 shares. This is just over 23.18% of the total shares, with a market valuation of $7.18 million. Data from the same date shows that the other fund manager holds a little less at 996.33, or 23.09% of the shares, all valued at about 7.15 million.
